<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pediatrics</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatrics</journal-id>
<journal-id journal-id-type="hwp">pediatrics</journal-id>
<journal-id journal-id-type="pmc">pediatrics</journal-id>
<journal-id journal-id-type="publisher-id">Pediatrics</journal-id>
<journal-title-group>
<journal-title>Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0031-4005</issn>
<issn pub-type="epub">1098-4275</issn>
<publisher>
<publisher-name>American Academy of Pediatrics</publisher-name>
<publisher-loc>Elk Grove Village, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29101226</article-id>
<article-id pub-id-type="pmc">5703775</article-id>
<article-id pub-id-type="publisher-id">peds.2016-4040</article-id>
<article-id pub-id-type="doi">10.1542/peds.2016-4040</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>25.00</subject>
<subject>37.00</subject>
<subject>37.01</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Davis</surname>
<given-names>Peter E.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Filip-Dhima</surname>
<given-names>Rajna</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff4">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sideridis</surname>
<given-names>Georgios</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peters</surname>
<given-names>Jurriaan M.</given-names>
</name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2">a</xref>
<xref ref-type="aff" rid="aff1">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Au</surname>
<given-names>Kit Sing</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Northrup</surname>
<given-names>Hope</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bebin</surname>
<given-names>E. Martina</given-names>
</name>
<degrees>MD</degrees>
<degrees>MPA</degrees>
<xref ref-type="aff" rid="aff6">f</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Joyce Y.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff7">g</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krueger</surname>
<given-names>Darcy</given-names>
</name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff8">h</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2">a</xref>
<xref ref-type="aff" rid="aff4">b</xref>
</contrib>
<contrib contrib-type="author">
<collab>on behalf of the Tuberous Sclerosis Complex Autism Center of Excellence Research Network</collab>
</contrib>
<aff id="aff1"><label>d</label>Division of Epilepsy and Clinical Neurophysiology,</aff>
<aff id="aff2"><label>a</label>Departments of Neurology and</aff>
<aff id="aff3"><label>c</label>Pediatrics, and</aff>
<aff id="aff4"><label>b</label>F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts;</aff>
<aff id="aff5"><label>e</label>Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas;</aff>
<aff id="aff6"><label>f</label>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama;</aff>
<aff id="aff7"><label>g</label>Division of Pediatric Neurology, University of California at Los Angeles Mattel Children’s Hospital, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; and</aff>
<aff id="aff8"><label>h</label>Department of Neurology and Rehabilitation Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio</aff>
</contrib-group>
<author-notes>
<corresp id="cor9">Address correspondence to Mustafa Sahin, MD, PhD, Department of Neurology, Boston Children’s Hospital, 300 Longwood Ave, Boston, MA 02115. E-mail: <email>mustafa.sahin@childrens.harvard.edu</email></corresp>
<fn fn-type="COI-statement" id="fn14" specific-use="conflict">
<p><bold>POTENTIAL CONFLICT OF INTEREST:</bold> Dr Bebin serves on the scientific advisory board for Novartis Pharmaceuticals Corporation and GW Pharmaceuticals and receives clinical research support from both. Dr Wu serves on the professional advisory board for the Tuberous Sclerosis Alliance, has received honoraria from and serves on the scientific advisory board and the speakers’ bureau for Novartis and H. Lundbeck A/S, and has received research support from the Tuberous Sclerosis Alliance, Novartis, and Today’s and Tomorrow’s Children Fund. Dr Sahin has received research funding from F. Hoffman-La Roche AG, Novartis, Pfizer, and LAM Therapeutics; has served on the scientific advisory board of Sage Therapeutics Inc. and PTEN Research Foundation; and serves on the professional advisory board of the Tuberous Sclerosis Alliance. Dr Krueger has received research funding from Novartis, the Clack Foundation Inc., and the Tuberous Sclerosis Alliance; has received consultant fees from Novartis; and serves on the professional advisory board of the Tuberous Sclerosis Alliance. The other authors have indicated they have no potential conflicts of interest to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>140</volume>
<issue>6</issue>
<elocation-id>e20164040</elocation-id>
<history>
<date date-type="accepted">
<day>25</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 by the American Academy of Pediatrics</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri xlink:href="PEDS_20164040.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="precis">
<p>Infants with TSC can often be identified before neurologic symptoms present, allowing for improved surveillance and the possibility of disease-modifying treatment.</p>
</abstract>
<abstract>
<sec id="s01">
<title>OBJECTIVES:</title>
<p>Tuberous sclerosis complex (TSC) is a neurocutaneous genetic disorder with a high prevalence of epilepsy and neurodevelopmental disorders. TSC can be challenging to diagnose in infants because they often do not show many clinical signs early in life. In this study, we describe the timing and pattern of presenting and diagnostic features in a prospective longitudinal study of infants with TSC.</p>
</sec>
<sec id="s02">
<title>METHODS:</title>
<p>Two multicenter, prospective studies enrolled 130 infants with definite TSC by clinical or genetic criteria and followed them longitudinally up to 36 months of age. Periodic study visits included medical and seizure histories, physical and neurologic examinations, and developmental assessments. Ages at which major and minor features of TSC and seizures were first identified were analyzed.</p>
</sec>
<sec id="s03">
<title>RESULTS:</title>
<p>The most common initial presenting features of TSC were cardiac rhabdomyomas (59%) and hypomelanotic macules or other skin findings (39%), and 85% of infants presented with either or both. Ultimately, the most prevalent diagnostic TSC features were hypomelanotic macules (94%), tubers or other cortical dysplasias (94%), subependymal nodules (90%), and cardiac rhabdomyomas (82%). Thirty-five percent of infants presented prenatally, 41% presented at birth or within the first month of life, and 74% met criteria for TSC diagnosis at or within 30 days of presentation. Seizure onset occurred before or at initial presentation in only 15% of infants, but 73% developed epilepsy within the first year of life.</p>
</sec>
<sec id="s04">
<title>CONCLUSIONS:</title>
<p>Infants with TSC can often be identified early, before the onset of neurologic sequelae, enabling earlier diagnosis, surveillance, and possibly disease-modifying treatment.</p>
</sec>
</abstract>
<counts>
<fig-count count="5"></fig-count>
<table-count count="7"></table-count>
<equation-count count="1"></equation-count>
<ref-count count="49"></ref-count>
<page-count count="11"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>